Study extension for people on pembrolizumab, testing long-term safety
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial follows people with advanced tumors who are already on pembrolizumab (or similar treatment) to check long-term safety and effectiveness. It may help your care team by monitoring benefits and side effects over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are already in a qualifying pembrolizumab study (MK-3475-587) and are receiving or recently received the study drug there
- You have not started any new cancer treatment since your last pembrolizumab (or related combination) dose in the first part of the study
- Your overall health/energy level is good (ECOG score 0 or 1)
- Your organs are working well enough for study treatment (your clinic will check blood/organ test results)
- Any side effects from the first part of pembrolizumab are mostly gone or mild (Grade 1 or less, except hair loss)
- If you are pregnant/breastfeeding or could become pregnant/father children, you must meet strict contraception and pregnancy rules
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a new cancer drug (S-531011) in people with advanced or metastatic solid tumors, either by itself or combined with an immunotherapy drug. It may help shrink tumors and learn how the treatment works, but it also requires extra procedures like repeat tumor biopsies and frequent monitoring.
This early-stage trial tests a new investigational drug (ADG126) combined with pembrolizumab in people with advanced or metastatic solid tumors. It aims to find a safe dose and see whether the combination can shrink tumors.
This Phase 1/2 study tests pembrolizumab (an immune-based cancer treatment) either alone or with chemotherapy in people newly diagnosed with stage IV non-small cell lung cancer (NSCLC). It looks at how well the treatments work and whether they are safe, especially in people who haven’t had treatment yet for metastatic disease.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This study tests a new drug called PLN-101095 in people with advanced solid tumors whose cancer has stopped responding to a common immunotherapy. The goal is to see if combining this new drug with pembrolizumab can help control the cancer again.
This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.